CHARACTERISTICS AND CLINICAL OUTCOMES IN PATIENTS WITH CIRRHOSIS DUE TO METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE (MASLD) IN SWEDEN

被引：0
|
作者：
Shang, Ying [1 ]
Zhang, Xiao [2 ]
Fernandes, Gail [2 ]
Melaragno, Matthew [2 ]
Engel, Samuel [2 ]
Vessby, Johan [3 ]
Ekstedt, Mattias [4 ]
Hagstrom, Hannes [1 ]
机构：
[1] Karolinska Inst, Stockholm, Sweden
[2] Merck & Co Inc, Rahway, NJ USA
[3] Uppsala Univ Hosp, Uppsala, Sweden
[4] Linkoping Univ, Linkoping, Sweden
来源：
HEPATOLOGY | 2024年 / 80卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
1085
引用
收藏
页码：S821 / S822
页数：2
相关论文
共 50 条
  • [1] Evolutionary aspects of metabolic dysfunction-associated steatotic liver disease (MASLD)
    Geier, Andreas
    Schiffels, Stephan
    Krawczyk, Marcin
    GASTROENTEROLOGIE, 2025,
  • [2] Evaluation of a Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) Clinical Pharmacy Service
    Sallam, Sandy
    Ahmed, Aijaz
    Gu, Xin
    DIABETES, 2024, 73
  • [3] Evaluation of metabolic dysfunction-associated steatotic liver disease (MASLD) terminology in different clinical settings
    Iruzubieta, Paula
    Santos-Laso, Alvaro
    Arias-Loste, Maria Teresa
    Calleja, Jose Luis
    Crespo, Javier
    JOURNAL OF HEPATOLOGY, 2024, 80 (03) : e121 - e123
  • [4] Roles of Activin A and Gpnmb in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
    Liu, Huan
    Yerevanian, Armen
    Westerhoff, Maria
    Hastings, Margaret H.
    Guerra, Justin Ralph Baldovino
    Zhao, Meng
    Svensson, Katrin J.
    Cai, Bishuang
    Soukas, Alexander A.
    Rosenzweig, Anthony
    DIABETES, 2024, 73 (02) : 260 - 279
  • [5] Lipotoxicity-driven metabolic dysfunction-associated steatotic liver disease (MASLD)
    Iturbe-Rey, Santiago
    Maccali, Claudia
    Arrese, Marco
    Aspichueta, Patricia
    Oliveira, Claudia P.
    Castro, Rui E.
    Lapitz, Ainhoa
    Izquierdo-Sanchez, Laura
    Bujanda, Luis
    Perugorria, Maria J.
    Banales, Jesus M.
    Rodrigues, Pedro M.
    ATHEROSCLEROSIS, 2025, 400
  • [6] Clusters of metabolic dysfunction-associated steatotic liver disease for precision medicine MASLD
    Stefan, Norbert
    Targher, Giovanni
    NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY, 2025, : 226 - 227
  • [7] Does Resveratrol Improve Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)?
    Kasprzak-Drozd, Kamila
    Nizinski, Przemyslaw
    Kasprzak, Paulina
    Kondracka, Adrianna
    Oniszczuk, Tomasz
    Rusinek, Agata
    Oniszczuk, Anna
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2024, 25 (07)
  • [8] Exploring Autoantibodies as Predictors of Severe Fibrosis or Cirrhosis in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) Response
    Faisal, Nabiha
    Minuk, Gerald
    CANADIAN LIVER JOURNAL, 2024, 7 (04): : 417 - 418
  • [9] Patients Admitted With Sepsis and Gastrointestinal Bleeding, Affected by Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), Exhibit Worse Clinical Outcomes
    Oum, Muhamad
    Albuni, Mhd Kutaiba
    Sawaf, Bisher
    Aloum, Khalid
    Sekhon, Sandeep
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2024, 119 (10S): : S1437 - S1437
  • [10] Platelet dynamics in metabolic patients with metabolic dysfunction-associated steatotic liver disease/steatohepatitis and liver cirrhosis
    Zoncape, Mirko
    Castelli, Marco
    Sacerdoti, David
    Minuz, Pietro
    Dalbeni, Andrea
    JOURNAL OF HEPATOLOGY, 2024, 80 : S492 - S493
12345